Novo Nordisk sues Eli Lilly over "deceptive" GLP-1 drug ad campaign

Full text

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’re sending the newsletter a bit earlier today to get you some news out of federal court.

The need-to-know this morning

Novartis reported second-quarter earnings and reaffirmed its 2026 guidance.

Agios Pharmaceuticals is discontinuing the development of a next-generation drug called tebapivat for sickle cell disease. A Phase 2 study did not establish a “differentiated profile to support continued development,” the company said.

Novo sues Lilly as GLP-1 fight escalates

Novo Nordisk this morning sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.

Continue to STAT+ to read the full story…